Asthma Management Key Management Parameters
Patient’s Name ______________________ MRN # _____________ Asthma Diagnosis Confirmed? Yes o No o
CLASSIFY SEVERITY: DAILY MEDICATIONS REQUIRED TO CLINICAL FEATURES BEFORE MAINTAIN LONG-TERM CONTROL TREATMENT OR ADEQUATE CONTROL *Preferred Treatment in Bold Print Preferred Treatment SEVERE PERSISTENT PEF or FEV PEF Variability > 30%
• Corticosteroid tablets or syrup long term (2mg/kg/
day, generally do not exceed 60 mg per day). Make
repeat attempts to reduce systemic corticosteroids and
maintain control with high-dose inhaled corticosteroids
Preferred Treatment
• Low-to-medium dose inhaled corticosteroids
MODERATE PERSISTENT PEF or FEV PEF Variability > 30% Alternative Treatment
• Increase inhaled corticosteroids within medium-dose
range OR Low-to-medium dose inhaled corticosteroids
and either leukotriene modifier or theophylline. Consider Xolair if perennial allergies exist for those with moderate or severe persistent disease.
**Xolair needs prior auth for all insurers and dosing should be based upon FDA approved IgE levels and body weight
Preferred Treatment MILD PERSISTENT PEF or FEV ≥ 80% Alternative Treatment PEF Variability 20-30%
• cromolyn, leukotriene modifier, nedocromil, OR
sustained release theophylline to serum concentration
MILD INTERMITTENT No daily medication needed PEF or FEV > 80%
• Severe exacerbations may occur, separated by long
PEF Variability < 20%
periods of normal lung function and no symptoms.
tA course of systemic corticosteroids is recommended. Risk Assessment: Perform for all levels
Has the patient required urgent/emergent care and/or oral steroids two or more times in the past year?
If so, increase the level of maintenance treatment by at least one severity.
STEP DOWN (decrease medications, when possible)
• Short-acting bronchodilator: 2 puffs short-acting inhaled beta2-agonists as
Review treatment every 1 to 6 months; a gradual
needed for symptoms. (These agents should not be used more than 6 times a
stepwise reduction in treatment may be possible.
day as increased use is associated with decreased responsiveness.)
STEP UP (increase medications, when needed)
If control is not maintained, consider step up. First,
• Use of short-acting beta2-agonists > 2 times a week in intermittent asthma
review patient medication technique, adherence, and
(daily, or increasing use in persistent asthma) may indicate the need to initiate
(increase) long-term control therapy.
• Intensity of treatment will depend on severity of exacerbation; may repeat
doses of quick relief medications every 20 minutes in an emergency situation,
but should seek immediate medical evaluation for possible steroid burst. mercy.net Asthma Management Key Management Parameters ASSESS LEVEL OF CARE Daytime symptoms/day/week/mo
Severity ClassificationAsthma Control Test Score
more information ASSESS RISK LEVEL Spirometry (annually) Number of ER/UC recent and/or MEDICATIONS: C = CONTRAINDICATED, R = REFUSED, A = ALLERGIC PATIENT EDUCATION Asthma Management Action Plan
Patient’s Name _______________________ MRN # _____________ Primary Care Physician: _____________________
“CAUTION ALERT” ALLERGIES TO “MEDICAL ALERT” MEDICATIONS “ALL CLEAR”
contacting your health care provider every time you drop
Best Peak Flow: ________ Greater than _____ (80%) or
CONTROLLER MEDICATIONS (Usually only one of these agents will be used at a Remember: You should not
long acting bronchodilator to stay in the Red Zone for more
scribed, for one or two weeks instructions from your physi-
LEUKOTRIENE MODI- (Do not use more than one MEDICATIONS of these agents) (Do not use more than one
Inhale 2 puffs every 4 hours, of these agents)
(or nebulize rescue solution, (or nebulize rescue solution,
if nebulizer medication is be- if nebulizer medication is be-
Recheck peak flow before MISCELANEOUS (Do not use more than one (Do not use more than one next dose agent from each category) agents from each category)
Inhale as directed daily (if di- Inhale as directed, especially
rected to do so) or as needed if cough is productive
Nebulize 1 vial 3 times a day Nebulize 1 vial 3 times a day to Step 1) and continue this
ORAL STEROIDS *** Initiate rescue dose of (These medications may be prescribed regularly for moder- steroid if prescribed *** ate or severe persistent disease)
Take _____ tablets _____ times a day for ___________
Take _____ tablets _____ times a day for ___________
Asthma Management Medications RESCUE INHALERS OR NEBULIZER SOLUTIONS
Albuterol (proair, **proventil, ventolin)
PREVENTIVE MEDICATIONS
Corticosteroid inhalers or nebulizer solution
Budesonide (pulmicort flexhaler, pulmicort respules)
Fluticasone (flovent diskus, flovent hfa)
Long acting bronchodilator inhalers or nebulizer solution
(Caution: must use with a corticosteroid agent)
Formoterol (foradil aerolizer, perforomist)
Combination corticosteroid and long acting bronchodilators
Salmeterol-fluticasone (advair diskus, advair hfa)
MISCELLANEOUS AGENTS
Albuterol-ipatroprium (combivent, duoneb)
ORAL STEROIDS
DATASHEET Epiphen Solution (Vétoquinol UK Limited) Epiphen Solution Use of phenobarbitone in conjunction with primidone is notrecommended as primidone is predominantly metabolised tophenobarbitone. Presentation: Solution containing 4% Phenobarbitone PhEur Phenobarbitone may reduce the activity of some drugs by increasingthe rate of metabolism through induction of drug-metabolisingen
Sub-conference 3: Organic and polymeric nanomaterials Sept. 7, 2011 (Wed.), Venue: Room 401 Time Chair Affiliation Session 1 : Organic Photovoltaics Self-Assembly, Properties, and Applications in Photovoltaic materials for high performance Yongfang Exploring a Soluble High Molecular Weight Polymer for Organic Photovoltaic Device Wanyi Nie Application: From Spin Coating t